TScan Therapeutics annual debt-to-equity ratio
2021
2022
2023
2024
2025
TScan Therapeutics Debt-to-Equity Ratio Growth & History (TCRX)
TScan Therapeutics's debt-to-equity ratio was 0.76 for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.76 | 0.36 | +89.20% |
| 2024 | 2024-12-31 | 0.40 | −0.21 | −34.04% |
| 2023 | 2023-12-31 | 0.61 | −0.25 | −29.15% |
| 2022 | 2022-12-31 | 0.86 | 0.83 | +2200.68% |
| 2021 | 2021-12-31 | 0.04 | — | — |
TScan Therapeutics quarterly debt-to-equity ratio
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.32 | 0.77 | +140.66% |
| Q1 2026 | 2026-03-31 | 0.95 | 0.49 | +106.82% |
| Q4 2025 | 2025-12-31 | 0.76 | 0.36 | +89.20% |
| Q3 2025 | 2025-09-30 | 0.66 | 0.27 | +68.34% |
| Q2 2025 | 2025-06-30 | 0.55 | 0.19 | +53.35% |
| Q1 2025 | 2025-03-31 | 0.46 | −0.28 | −38.14% |
| Q4 2024 | 2024-12-31 | 0.40 | −0.21 | −34.04% |
| Q3 2024 | 2024-09-30 | 0.39 | −0.12 | −23.39% |
| Q2 2024 | 2024-06-30 | 0.36 | −0.10 | −22.48% |
| Q1 2024 | 2024-03-31 | 0.75 | −0.35 | −31.76% |
| Q4 2023 | 2023-12-31 | 0.61 | −0.25 | −29.15% |
| Q3 2023 | 2023-09-30 | 0.51 | 0.22 | +77.16% |
| Q2 2023 | 2023-06-30 | 0.46 | 0.42 | +1056.07% |
| Q1 2023 | 2023-03-31 | 1.09 | 1.05 | +2721.73% |
| Q4 2022 | 2022-12-31 | 0.86 | 0.83 | +2200.68% |
| Q3 2022 | 2022-09-30 | 0.29 | 0.25 | +689.03% |
| Q2 2022 | 2022-06-30 | 0.04 | — | — |
| Q1 2022 | 2022-03-31 | 0.04 | — | — |
| Q4 2021 | 2021-12-31 | 0.04 | — | — |
| Q3 2021 | 2021-09-30 | 0.04 | — | — |
TScan Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, TScan Therapeutics's debt-to-equity ratio increased from 0.04 to 0.76, a change of 0.73. The latest reported quarter, Q2 2026, shows 1.32.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗